CO-DEVELOPMENT AND COMMERCIALIZATION AGREEMENTCo-Development and Commercialization Agreement • October 26th, 2012 • RedHill Biopharma Ltd. • Pharmaceutical preparations • London
THIS CO-DEVELOPMENT AND COMMERCIALIZATION AGREEMENT (this “Agreement”) is made and entered into as of August 26, 2010 (the “Effective Date”), by and between IntelGenx Corp., a Canadian corporation (“IntelGenx”), and RedHill Biopharma Ltd., an Israeli company (“RedHill”). IntelGenx and RedHill each may be referred to herein individually as a “Party,” or collectively as the “Parties”.
ASSET PURCHASE AGREEMENTAsset Purchase Agreement • October 26th, 2012 • RedHill Biopharma Ltd. • Pharmaceutical preparations • New South Wales
This Asset Purchase Agreement is made and entered into as of August 11, 2010 (the "Effective Date"), by and among Giaconda Limited ABN 68 108 088 517, an Australian public limited company having its registered office at Ground Floor, 44 East Street, Five Dock, NSW 2046 Australia (the "Seller") and RedHill Biopharma Ltd., an Israeli company, having its business address at 42 Givati Street, Ramat-Gan 52232, Israel (the "Buyer").
EXCLUSIVE LICENSE AGREEMENTExclusive License Agreement • October 26th, 2012 • RedHill Biopharma Ltd. • Pharmaceutical preparations • London
THIS EXCLUSIVE LICENSE AGREEMENT (this “Agreement”) is made and entered into as of May 2, 2010 (the “Effective Date”), by and between SCOLR Pharma Inc., a Delaware corporation (“SCOLR”), and RedHill Biopharma Ltd., an Israeli company (“RedHill”). SCOLR and RedHill each may be referred to herein individually as a “Party,” or collectively as the “Parties”.
EXCLUSIVE LICENSE AGREEMENTExclusive License Agreement • October 26th, 2012 • RedHill Biopharma Ltd. • Pharmaceutical preparations • England
THIS EXCLUSIVE LICENSE AGREEMENT (this “Agreement”) is made and entered into effective as of November 18, 2009 (the “Effective Date”), by and between Egalet a/s, a Danish corporation also registered under the name BM Research a/s (“Egalet”), and RedHill Biopharma Ltd., an Israeli company (“RedHill”). Egalet and RedHill each may be referred to herein individually as a “Party,” or collectively as the “Parties”.
RESEARCH and TECH TRANSFER, MANUFACTURING AND SUPPLY AGREEMENT FOR RHB-104 [Clinical Trial Batches Only]Tech Transfer, Manufacturing and Supply Agreement • October 26th, 2012 • RedHill Biopharma Ltd. • Pharmaceutical preparations • Quebec
This TECH TRANSFER, MANUFACTURING AND SUPPLY AGREEMENT (“Agreement”) is made as of this 28th day of April, 2011, (the «Effective Date») by and between 7810962 CANADA INC., a corporation having its principal place of business at 245 Victoria Ave, Suite 100, Montreal, QC H3Z 2M6, Canada, (“PROVIDER”) and RedHill Biopharma Ltd., with principle place of business at 42 Givati St. Ramat-Gan 52232, Israel (“CUSTOMER”). UMAN and CUSTOMER shall be collectively referred as the “Parties”, with each being a “Party”.
Loan AgreementLoan Agreement • October 26th, 2012 • RedHill Biopharma Ltd. • Pharmaceutical preparations • Tel-Aviv
This Loan Agreement is made and entered into as of the date set forth on the signature page below by and between RedHill Biopharma Ltd., a company organized and registered under the laws of the State of Israel, with offices at 42 Givati Street, Ramat-Gan, 52232, Israel (“Borrower”) and the person or entity whose name, signature and address appear on the signature page hereof (“Lender”).
INDEPENDENT CONSULTING AGREEMENTIndependent Consulting Agreement • October 26th, 2012 • RedHill Biopharma Ltd. • Pharmaceutical preparations
This Independent Consulting Agreement ("Agreement") is made by and among RedHill Biopharma Ltd., having an address at 42 Givati St. Ramat-Gan 52232 Israel (the “Company”), and R.E. Investments, with an address at R.E.Investments bvba, Zeedijk 842 bus 34, 8300 Knokke, Belgium, BE 0874.456.874, represented hereby by Benjamin Van Oudenhove (“the Consultant”).
THE SYMBOL "****" DENOTES PLACES WHERE PORTIONS OF THIS DOCUMENT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT. SUCH MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. MASTER SERVICE AGREEMENT for...Master Service Agreement • October 26th, 2012 • RedHill Biopharma Ltd. • Pharmaceutical preparations
AND: 7810962 Canada Inc (doing Business under the name “InSymbiosis”), a body politic and corporate, duly incorporated according to the laws of Canada and with principle place of business at 245 Victoria Ave, Suite 100, Montreal, Quebec, H3Z 2M6, Canada,
FEE AGREEMENTFee Agreement • October 26th, 2012 • RedHill Biopharma Ltd. • Pharmaceutical preparations • London
This agreement (this “Agreement”) sets forth the terms of the agreement between a RedHill Biopharma Ltd., together with its subsidiaries, affiliates, shareholders, stakeholders (the “Company”) and ProSeed Capital Holdings CVA (together with its subsidiaries and affiliates, “ProSeed”), pursuant to which the Company has agreed to engage ProSeed, on a non-exclusive basis, to perform certain advisory services, as described herein. Specifically, the Company and ProSeed agree as follows:
THE SYMBOL "****" DENOTES PLACES WHERE PORTIONS OF THIS DOCUMENT HAVE BEEN OMIITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT. SUCH MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSIONTerms of Service Agreement • October 26th, 2012 • RedHill Biopharma Ltd. • Pharmaceutical preparations • Quebec
BETWEEN: 7810962 Canada Inc., a corporation duly incorporated under the laws of Canada and having its principal place of business at 5320 13e Avenue, Montréal, Québec, H1X 2X8;
Underwriting Agreement that was prepared and signed in Tel Aviv on the 30th of the month of January, 2011Underwriting Agreement • October 26th, 2012 • RedHill Biopharma Ltd. • Pharmaceutical preparations
Whereas It is the intention of the Company to publish a Prospectus (hereinafter: the “Prospectus”) in January 2011, in which it will offer to the public 13,100,000 ordinary shares of the Company each of NIS 0.01 nominal value together with 6,550,000 Series 1Warrantsthat may be realized into the Company’s ordinary shares (hereinafter: the “Offered Securities”); and
Convertible Loan AgreementConvertible Loan Agreement • October 26th, 2012 • RedHill Biopharma Ltd. • Pharmaceutical preparations • Tel-Aviv
This Convertible Loan Agreement is made and entered into as of the last date set forth on the signature page below by and between RedHill Biopharma Ltd., a company organized and registered under the laws of the State of Israel, with offices at 42 Givati Street, Ramat-Gan, 52232, Israel (“Borrower”) and the person or entity whose name, signature and address appear on the signature page hereof (“Lender”).
CONFIDENTIAL FINALPatent License Agreement • October 26th, 2012 • RedHill Biopharma Ltd. • Pharmaceutical preparations • Florida
THE SYMBOL "****" DENOTES PLACES WHERE PORTIONS OF THIS DOCUMENT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT. SUCH MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.
